Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
批准号:
10618242
负责人:
Mark J. Zylka
金额:
$85.2万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-06-01 至 2027-04-30
关键词:
AffectAttentionAttention deficit hyperactivity disorderBiological MonitoringBrainCRISPR/Cas technologyChemical ExposureChemicalsDataDevelopmentDevelopmental Delay DisordersDiseaseEnd Point AssayEngineeringEnvironmentEnvironmental HealthEnvironmental Risk FactorExposure toFuture GenerationsGene MutationGeneticGoalsHeritabilityHome environmentHumanImpairmentIndividualJointsKnowledgeLinkLongevityMaternal ExposureMitochondriaMolecular TargetMutationNeurodevelopmental DisorderNeuronsPathologyPathway interactionsPersonsPesticidesPlacentaPlasticsPredispositionPregnancyPrevalenceProcessPublic HealthResearchResearch PersonnelRiskSamplingTimeValproic AcidWorkautism spectrum disorderbehavioral phenotypingbuilding materialscritical periodfungicidehigh throughput screeninghuman modelin vivomouse modelmucidinnerve stem cellprenatal exposureprogramspyrethroid
中文摘要
项目总结
虽然在识别与自闭症风险有关的从头基因突变方面取得了重大进展,但许多
人们对环境风险以及这些风险导致自闭症病理的程度关注较少。
在易感人群中。环境因素,包括孕期接触拟除虫菊酯农药和
丙戊酸,与自闭症的风险有关。产前接触拟除虫菊酯也与患上
发育迟缓和注意缺陷多动障碍(ADHD)--最常见的
神经发育障碍。然而,这些环境风险是在经过一段时间的回顾后确定的
大量的人被暴露。数以千计的化学品被登记用于环境中,并且
人类可能在不同程度上接触到其中许多化学物质,包括塑料中的化学物质。
和建筑材料。我们目前缺乏一种方法来系统地评估哪些环境使用的化学品
对发育中的大脑有最大的潜在危害。无法识别对环境的威胁
大脑早期--在它们引发疾病之前--代表着我们这个时代的主要公共卫生挑战之一。
这一挑战与自闭症尤其相关,目前美国每59个人中就有一个受到自闭症的影响,
遗传性研究表明,遗传和环境因素导致了自闭症的风险。我们的研究
该计划的指导思想是这样一种假设,即自闭症和其他疾病的“候选”环境风险
神经发育障碍可以通过识别化学物质和混合物来合理识别
与这些疾病有关的靶分子通路。我们的长期目标是1)确定
环境用化学品和混合物,目标是与神经发育有关的分子途径
精神错乱。这些研究将利用原代人类神经前体细胞(PhNPC)、原代神经元和
与高通量筛选兼容的终端。2)评估现实世界中的风险敞口
化学品/混合物。如果环境采样和生物监测数据不适用于这些
化学品/混合物,我们将与环境健康科学(EHS)研究人员网络合作,收集
这些数据。3)使用野生型和CRISPR/Cas9工程小鼠建立模型,评估体内暴露风险
人类自闭症相关突变。我们将优先处理a)影响一种或多种化学品/混合物
PhNPC/神经元检测终点,b)已证实对人体有暴露风险,c)进入胎盘和/或
母亲暴露后发育中的大脑。虽然具体的项目将随着时间的推移而发展,但我们计划
最初的重点是单独和联合暴露于拟除虫菊酯和百菌灵-一种新型杀菌剂,
抑制线粒体。这两类化学物质都会损害神经元功能,并在家庭环境中共同出现。
我们将评估产前接触这些和其他优先化学品和混合物的程度
加重与自闭症和其他神经发育障碍相关的大脑和行为表型
在整个生命周期内。
英文摘要
PROJECT SUMMARY
While significant progress has been made in identifying de novo gene mutations linked to autism risk, much
less attention has been paid to environmental risks and the extent to which these risks cause autism pathology
in susceptible individuals. Environmental factors, including gestational exposure to pyrethroid pesticides and
valproic acid, are implicated in risk for autism. Prenatal exposure to pyrethroids is also linked to risk for
developmental delay and attention deficit hyperactivity disorder (ADHD)—one of the most common
neurodevelopmental disorders. However, these environmental risks were identified retrospectively, after a
large number of people were exposed. Thousands of chemicals are registered for use in the environment, and
humans are potentially exposed to many of these chemicals to varying degrees, including chemicals in plastics
and building materials. We currently lack a way to systematically evaluate which environmental-use chemicals
have the greatest potential to harm the developing brain. The inability to identify environmental threats to the
brain early—before they cause disease—represents one of the major public health challenges of our time.
This challenge is particularly relevant to autism, which now affects 1 in 59 individuals in America, and where
heritability studies indicate that genetic and environmental factors contribute to autism risk. Our research
program is guided by the hypothesis that “candidate” environmental risks for autism and other
neurodevelopmental disorders can be identified rationally, by identifying chemicals and mixtures that
target molecular pathways implicated in these disorders. Our long term goals are to 1) identify
environmental-use chemicals and mixtures that target molecular pathways implicated in neurodevelopmental
disorders. These studies will utilize primary human neural progenitor cells (phNPCs), primary neurons, and
endpoints that are compatible with high-throughput screening. 2) Assess real world exposure to these
chemicals/mixtures. If environmental sampling and biomonitoring data are not available for these
chemicals/mixtures, we will work with a network of Environmental Health Science (EHS) researchers to collect
these data. 3) Evaluate exposure risk in vivo using wild-type and CRISPR/Cas9-engineered mice that model
human de novo autism-linked mutations. We will prioritize chemicals/mixtures that a) impact one or more
phNPC/neuron assay endpoints, b) are verified exposure risks to humans, and c) enter the placenta and/or
developing brain following maternal exposure. While the specific projects will evolve over time, we plan to
initially focus on individual and joint exposures to pyrethroids and strobilurins—a new class of fungicides that
inhibits mitochondria. Both chemical classes impair neuronal functions and co-occur in the home environment.
We will evaluate the extent to which prenatal exposure to these and other prioritized chemicals and mixtures
exacerbate brain and behavioral phenotypes associated with autism and other neurodevelopmental disorders
across the lifespan.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10094266
-
项目类别:
-
资助金额:$36.22万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10579988
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10717670
-
项目类别:
-
资助金额:$3.97万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
-
批准号:10349447
-
项目类别:
-
资助金额:$37.61万
-
财政年份:2020
-
负责人:Mark J. Zylka
-
依托单位:
CRISPR/Cas9-based gene therapy for Angelman syndrome
-
批准号:10490828
-
项目类别:
-
资助金额:$54.07万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
CRISPR/Cas9-based gene therapy for Angelman syndrome
-
批准号:10237150
-
项目类别:
-
资助金额:$58.61万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
-
批准号:10402265
-
项目类别:
-
资助金额:$85.2万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
CRISPR/Cas9-based gene therapy for Angelman syndrome
-
批准号:10011898
-
项目类别:
-
资助金额:$56.99万
-
财政年份:2019
-
负责人:Mark J. Zylka
-
依托单位:
Identification of candidate environmental risks for autism
-
批准号:9525549
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2017
-
负责人:Mark J. Zylka
-
依托单位:
Lipid kinase regulation of pain signaling and sensitization
-
批准号:9279273
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
The Elongation Hypothesis of Autism
-
批准号:8899547
-
项目类别:
-
资助金额:$76.0万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
Lipid kinase regulation of pain signaling and sensitization
-
批准号:8627903
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
The Elongation Hypothesis of Autism
-
批准号:8560195
-
项目类别:
-
资助金额:$76.0万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
Lipid kinase regulation of pain signaling and sensitization
-
批准号:8723315
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2013
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:7763510
-
项目类别:
-
资助金额:$71.68万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:8541896
-
项目类别:
-
资助金额:$70.82万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:8144264
-
项目类别:
-
资助金额:$73.05万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
Harnessing ectonucleotidases to treat chronic pain
-
批准号:8332859
-
项目类别:
-
资助金额:$73.03万
-
财政年份:2009
-
负责人:Mark J. Zylka
-
依托单位:
BAC Technology
-
批准号:7620183
-
项目类别:
-
资助金额:$18.59万
-
财政年份:2008
-
负责人:Mark J. Zylka
-
依托单位:
Biochemical Modulation of Nociceptive Circuits
-
批准号:7347513
-
项目类别:
-
资助金额:$31.71万
-
财政年份:2007
-
负责人:Mark J. Zylka
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位: